Background: The ambulatory treatment of advanced heart failure (HF) with intermittent
Introduction
The rehospitalization of patients suffering from heart failure (HF) is associated with an increased risk of death [1] . Therefore, besides alleviating symptoms and enhancing the quality of life, the prevention of acute cardiac decompensation and hospitalizations is an important therapeutic objective, which might lower the long-term morbidity and mortality. In spite of recent therapeutic progress, patients presenting with American College of Cardiology/American Heart Association (ACC/AHA) stage D HF remain at high risk of hospitalization and death [5] . In these patients, the only interventions known to improve outcomes, beyond standard management, are cardiac transplantation and left ventricular assist devices, which are limited by the availability of donor organs, or by hemorrhagic, thromboembolic, and infectious complications. Thus, the need persists to find other means of lowering the rates of hospitalization and death.
Multiple studies have been published on the use of intermittent drug infusions in patients presenting with advanced HF [6-9]. While symptomatic improvements [6] and an increase in exercise tolerance [7] have been observed with inotropes, a retrospective analysis of the ADHERE registry found a significantly higher in-hospital mortality associated with the short-term administration of dobutamine or milrinone, than with vasodilator therapy with nitroglycerin or nesiritide [10] , suggesting that intermittent infusions of inotropes increase mortality [8] . On the other hand, in a randomized trial, infusions of a natriuretic peptide lowered neither mortality nor the rate of hospitalizations [9] .
We have studied the intermittent infusions of drugs in patients presenting with advanced HF since 1995 [11] . In contrast to several other studies of intermittent infusions, which administered a single inotrope or natriuretic peptide [6-9], we choose among different drugs with each infusion, depending on the baseline systolic blood pressure (BP), a strategy which might represent a progress in intermittent infusion therapy.
Methods

Patient selection
We evaluated all patients who received intermittent drug infusions in our hospital between May 2005 and July 2009. To be included in this analysis, the patients had to fulfill all the following criteria before the beginning of intermittent infusion therapy: 1) ≥2 hospitalizations for management of HF within the previous 12 months, 2) symptoms consistent with New York Heart Association (NYHA) functional class III or IV, 3) optimally treated with oral and device therapy, 4) had granted a written informed consent to participate in the study. Patients were excluded from intermittent infusion therapy if they had suffered an acute myocardial 6 infarction within 3 months, or presented with a) unstable angina, b) an estimated glomerular filtration rate <15 ml/min/1.73 m 2 or long-term dialysis, or c) pure right ventricular failure (e.g. primary pulmonary hypertension).
Informed consent
Written informed consent was obtained from all the participants of this study, and all study procedures were in compliance with the Declaration of Helsinki and the institutional guidelines of Hyogo Prefectural Amagasaki Hospital.
Infusion therapy
The drugs were administered intravenously for 3 or 4 h, once or twice weekly. The choices of drugs included a) the A-type natriuretic peptide, carperitide, b) olprinone, and c) dopamine or dobutamine. The pharmaceutical and infusion schedule were chosen by each individual physician. Carperitide was avoided when the systolic BP was <90 mmHg, and dopamine and dobutamine when the systolic BP was ≥110 mmHg. Boluses of furosemide were administered during the infusions as needed. The patients were hospitalized if HF worsened in spite of the twice-weekly infusions.
To confirm the short-term safety and tolerance of therapy, the electrocardiogram, BP and urine output (UO) were monitored throughout the infusions. BW, systolic and diastolic infusion. A patient was defined as a responder to therapy when the length and number of hospitalizations and costs were all decreased after, compared with before the intermittent infusions. To define pre-infusion period, we picked up all periods that patients were not hospitalized for >24 months, and the last one of those periods was defined as the start of pre-infusion period for each patient. In other words, pre-infusion period was defined so that 
Statistical analysis
The data are reported as means ± standard deviation (SD 
Results
Short-term effects of the infusions
The baseline characteristics of the 11 patients enrolled in the study are shown in table 1 By multiple linear regression analysis, using the variables listed in table 2, BW and dose of intravenous furosemide were independent predictors of UO during the infusions (Table 3) .
Long-term survival of the study population
Over a mean follow-up of 29.3±28.8 months (median = 20; range 2-104), 4 patients died, all from cardiac causes. By Kaplan-Meier analysis, the cumulative survival rate was 69.3% at 20 months (median follow-up), and 55.4% at 22 months ( Figure 1 ).
Effects of treatment on costs and hospitalizations
Comparing the mean pre-infusion period of 15.7±9.4 months with the post-infusion period of 29.3±28.8 months (Figure 2 ), the mean duration of hospitalizations for management of HF was shortened from 6.9±3.0 to 1.8±1.5 days/month (73.9%; p=0.017), the mean number of hospitalizations decreased from 0.36±0.14 to 0.17±0.18 (51.9%; p=0.007), and the mean cost was lowered from 216±86 to 93±68 10 3 yen (56.9%; p=0.021).
Among the 11 patients, 8 responded to the intermittent infusions treatment (Table 4) .
Compared with the non-responders, the patients who responded tended to have a greater baseline body mass index (p=0.12), slower HR (p=0.10), higher UO (p=0.15), and higher systolic BP (p=0.17).
Discussion
This is, to our knowledge, the first study of intermittent infusions for the management of HF, in which the pharmaceuticals administered, inotropes or natriuretic peptides, were chosen on the basis of the pre-treatment systolic BP. We found that this treatment strategy significantly decreased the length and numbers of hospitalizations, as well as overall medical costs.
Since our preliminary report [11], we have overcome several limitations by developing a system dedicated to the administration of intermittent infusion therapy, including the unlimited availability of beds in our ambulatory department. Furthermore, the longer duration of follow-up allowed a more reliable evaluation of the long-term safety of the treatment.
Safety and efficacy of intermittent infusions
The evaluation of the safety and efficacy of intermittent infusion therapy has not been standardized. On the short term, the UO, BP, HR, oxygen saturation, electrocardiogram and changes in BW should be monitored with each infusion. While these observations do not predictably correlate with clinical outcomes [12], they are essential in the evaluation of safety.
On the long term, survival and length and number of hospitalizations for management of HF are the most important endpoints. Quality of life is another important endpoint, which was not measured in this retrospective study, as the pre-infusion data were not available.
As a consequence of an aging population and greater proportion of survivors of acute coronary syndromes and cardiac decompensation, the costs of care for patients suffering from HF are increasing. While the economic impact of intermittent infusions has not been published previously, lowering these costs is as important as decreasing the rates of hospitalization or lowering mortality.
Selection of pharmaceuticals
The In all previous studies of intermittent infusions, the treatment was limited to a single drug, whether an inotrope or a natriuretic peptide. However, intermittent infusions of natriuretic peptide should be avoided in presence of low output or hypotensive state.
Phosphodiesterase inhibitors or a catecholamine should be chosen instead and, in presence of severe low output or hypotensive state, a catecholamine may be the only choice. Furthermore, since, in the same patient, the vital signs may vary, a choice of drug before each infusion is likely to be associated with better outcomes. The systolic BP below which natriuretic peptides should be avoided, or a catecholamine be used, has not been firmly established. Pending further studies, however, we believe that natriuretic peptides be avoided when the systolic BP is <90 mmHg, and dopamine or dobutamine when it is ≥110 mmHg, considering that we observed no adverse event in this study.
In this study, we chose not continuous but intermittent infusions because of concern about arrhythmia or changes in blood pressure. However, intermittent infusions may have weaker effect than continuous infusions, and should be compared with continuous infusions in the future.
Safety of intermittent infusions
The main immediate adverse effects of intermittent infusion therapy are hypotension and arrhythmias. In a randomized trial of intermittent infusions of nesiritide, a higher rate of symptomatic and asymptomatic hypotension was reported in the actively treated than in the placebo-treated group [9] . On the other hand, no increase in arrhythmias has been reported with intermittent infusions of inotropes [8], and we observed neither hypotension nor an increase in arrhythmias during the infusions in this study. This short-term safety was achieved by avoiding the administration of a) natriuretic peptides to patients presenting with hypotension, b) catecholamine whenever possible, c) high doses of pharmaceuticals.
The cumulative survival of our study population was 55.4% at 22 months. The survival rate of patients presenting with HF varies with the severity of disease, the age and race of the patient, and other factors. In absence of a large Japanese registry such as ADHERE [10], we found a study of Japanese patients suffering from advanced HF with similar clinical characteristics, including NYHA functional class III or IV, brain natriuretic peptide >170 pg/ml, 70% treated with an angiotensin-converting enzyme inhibitor, and 28%
with a beta-adrenergic blocker [17] . Although these patients (63.6±1.5 years of age) were, on average, younger than ours (71.0±8.4 years), their survival rate was about 55% at approximately 600 days. Therefore, the intermittent infusions do not appear to have increased the mortality rate, which is acceptable, considering the severity of our patients' clinical presentation.
Response to therapy
Out of our 11 patients, 3, who did not respond to the intermittent infusions, tended to have a lower baseline body mass index, faster HR, lower UO, and lower systolic BP. However, we couldn't find any predictor of response to intermittent infusion therapy in this small study population, and larger studies are warranted to determine the predictor. Diuretics activate the renin-angiotensin-aldosterone system in patients suffering from chronic HF, who are at risk of renal dysfunction and dehydration [16] . However, in that study, the UO of responders during the infusions tended to be greater, after adjustment for BW, and the dose of furosemide and BW were both independent predictors of UO during the infusions.
In addition, the ambulatory administration of intravenous diuretics decreases the rate of hospitalizations for management of HF [18] . Therefore, the addition of intravenous furosemide to the infusions may have increased the benefits conferred by the infusions of inotropes or natriuretic peptide. However, the optimal dose of furosemide remains to be determined.
Limitations of our study
In this study, which included a small patient population from a single institution, the effect of infusion therapy on hospitalizations and costs was assessed by comparison with pre-infusion periods of the same patients instead of control-group. Accordingly a larger, double-blind, multicenter trial is warranted. Moreover, because we didn't perform invasive hemodynamic measurement during infusions or at systematically planned timing, pulmonary capillary wedge pressure or cardiac output could not be assessed in this study. Further, because of concern about arrhythmia or changes in blood pressure, we chose not continuous but intermittent infusions, which might decrease the effect of infusions.
Conclusion
This is the first study of intermittent infusion therapy, in which inotropes or a natriuretic peptide were administered on the basis of the pre-treatment systolic BP. In 11 patients presenting with advanced HF, the infusions significantly decreased a) the length and rate of hospitalizations for management of HF and b) medical costs, without decreasing survival. Values are means ± SD, or numbers (%) of patients *for management of heart failure Values are regression coefficients (95% confidence intervals). Values are means ± SD, or numbers (%) of patients; *responders versus non-responders; **for management of heart failure ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
